Health and Healthcare
Why This Transfusion-Dependent Beta-Thalassemia Trial Is Taking Off
Published:
Last Updated:
Protagonist Therapeutics Inc. (NASDAQ: PTGX) shares jumped on Wednesday after the company announced preliminary results from its midstage study for patients with transfusion-dependent beta-thalassemia. Specifically, the results come from the firm’s Transcend Phase 2 study of PTG-300.
The most severe type of transfusion-dependent beta-thalassemia is characterized by severe anemia and a lifelong dependence on red blood cell transfusions that can lead to iron overload. Ultimately, the accumulation of iron can be toxic and lead to progressive multi-organ damage.
In the study, dose-related drug exposure and reductions from baseline serum iron and transferrin saturation levels were observed, with significant reductions at the 40 mg and 80 mg weekly doses.
These early results suggest the potential of finding an appropriate dose of PTG-300 for continued development in the treatment of beta-thalassemia.
The results from further study with additional dose regimens and longer follow-up, with clinical efficacy results are expected in 2020.
Dinesh V. Patel, Ph.D., Protagonist president and CEO, commented:
The consistent and significant effect on iron levels observed in normal healthy volunteers in a previous study, and now in patients with beta-thalassemia, provides strong rationale for potential utility of PTG-300 in blood disorders directly dependent on disruption of normal iron homeostasis in the body. We are encouraged by these findings and are continuing with our original plans of conducting clinical proof-of-concept studies with PTG-300 in different blood disorders such as beta-thalassemia, polycythemia vera, hereditary hemochromatosis, and an investigator sponsored study in myelodysplastic syndromes. We are well financed to conduct these studies and our corporate objective is to make data-driven decisions in 2020, with the intent of choosing our first clinical indication for a potential pivotal study to begin in 2021.
Shares of Protagonist Therapeutics traded up about 53% on Wednesday to $7.18, in a 52-week range of $4.47 to $16.67. The consensus price target is $20.17.
24/7 Wall St.The Average American Is Losing Momentum On Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4%1 today. Checking accounts are even worse.
But there is good news. To win qualified customers, some accounts are paying more than 7x the national average. That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn a $200 bonus and up to 7X the national average with qualifying deposits. Terms apply. Member, FDIC.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.